Inactive Instrument

Press Releases Satsuma Pharmaceuticals, Inc.

Equities

STSA

US80405P1075

Press Releases

Unlock all the news: Be the first to know and act before the market!

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting	23-06-16	AQ
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting	23-06-15	AQ
Satsuma Pharmaceuticals : Termination of Material Agreement - Form 8-K	23-06-08	PU
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine	23-05-19	AQ
SATSUMA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-05-18	AQ
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine	23-05-18	AQ
SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceuticals, Inc. - STSA	23-05-10	BU
SATSUMA PHARMACEUTICALS, INC. : Other Events (form 8-K)	23-05-03	AQ
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at the 75th American Academy of Neurology Annual Meeting	23-04-24	AQ
SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceuticals, Inc. - STSA	23-04-21	BU
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting	23-04-21	AQ
Satsuma Pharmaceuticals : SNBL to Acquire Satsuma Pharmaceuticals - Form 8-K	23-04-17	PU
SATSUMA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-04-17	AQ
SNBL to Acquire Satsuma Pharmaceuticals	23-04-16	AQ
SATSUMA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-28	AQ
SATSUMA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-03-28	AQ
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights	23-03-28	AQ
SATSUMA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-16	AQ
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference	23-02-02	AQ
SATSUMA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	22-12-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Satsuma Pharmaceuticals, Inc.

Equities

STSA

US80405P1075

Press Releases

Filters